4598
Delta-Fly Pharma,Inc.
Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2021
300,000
Mar 2022
300,000
Mar 2023
-
Mar 2024
-
Mar 2025
-
Operating profit(thousand JPY)
Mar 2021
-852,231
Mar 2022
-961,462
Mar 2023
-1,315,810
Mar 2024
-1,403,464
Mar 2025
-1,708,224
Operating profit margin(%)
Mar 2021
-284.08
Mar 2022
-320.49
Mar 2023
-
Mar 2024
-
Mar 2025
-
Profit before tax(thousand JPY)
Mar 2021
-859,372
Mar 2022
-964,064
Mar 2023
-1,325,760
Mar 2024
-1,426,891
Mar 2025
-1,718,662
Profit(thousand JPY)
Mar 2021
-862,585
Mar 2022
-967,302
Mar 2023
-1,328,788
Mar 2024
-1,429,393
Mar 2025
-1,721,164
Total assets(thousand JPY)
Mar 2021
2,161,192
Mar 2022
1,324,352
Mar 2023
906,817
Mar 2024
1,474,155
Mar 2025
434,334
Cash and cash equivalents(thousand JPY)
Mar 2021
2,088,612
Mar 2022
1,268,492
Mar 2023
844,341
Mar 2024
1,417,062
Mar 2025
338,829
Cash flows from operating activities(thousand JPY)
Mar 2021
-726,649
Mar 2022
-940,399
Mar 2023
-1,303,049
Mar 2024
-1,279,615
Mar 2025
-1,834,577
Cash flows from investing activities(thousand JPY)
Mar 2021
-505
Mar 2022
-
Mar 2023
-326
Mar 2024
207
Mar 2025
-206
Cash flows from financing activities(thousand JPY)
Mar 2021
875,313
Mar 2022
119,857
Mar 2023
882,617
Mar 2024
1,853,195
Mar 2025
756,696
Return on equity(%)
Mar 2021
-41.7
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Equity ratio(%)
Mar 2021
96.1
Mar 2022
93.1
Mar 2023
87
Mar 2024
83.6
Mar 2025
63.5
Earnings per share(JPY per share)
Mar 2021
-187.34
Mar 2022
-178.58
Mar 2023
-234.51
Mar 2024
-198.78
Mar 2025
-195.58
Net assets per share(JPY per share)
Mar 2021
390.87
Mar 2022
227.41
Mar 2023
123.91
Mar 2024
149.69
Mar 2025
28.36
Dividend per share(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Payout ratio(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.